28
Participants
Start Date
March 1, 2021
Primary Completion Date
March 25, 2024
Study Completion Date
December 31, 2024
TAS 102
"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
Department of Clinical Oncology, HKU, Hong Kong
Taiho Pharmaceutical Co., Ltd.
INDUSTRY
The University of Hong Kong
OTHER